Research use only. CagriSema as a combination product is investigational and not FDA-approved. While semaglutide is approved as a specific finished drug, the bulk research-grade peptide and any cagrilintide-plus-semaglutide co-formulation sold as a research chemical are NOT the approved medicine and have not been evaluated for safety, purity, or bioavailability as sold. Nothing here is medical advice or dosing guidance. Do not use these compounds on humans or animals.
CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), developed by Novo Nordisk and studied in the Phase 3 REDEFINE program. The pairing engages two distinct satiety systems at once. This guide covers what the combination is, the trial evidence behind it, and — critically — the difference between the approved drug semaglutide, the bulk peptide sold for research, and this unapproved co-formulation.
Legal status, up front: CagriSema as a combination is investigational and NOT approved for any use. Cagrilintide has never been approved as a standalone product. Semaglutide IS approved — but only as specific finished drugs (e.g., Ozempic, Wegovy) manufactured to defined standards. Bulk semaglutide peptide sold for research, and any research-chemical cagrilintide+semaglutide blend, are not those approved products and are sold strictly for laboratory research use only.
What Is CagriSema?
Semaglutide reduces appetite and food intake through the GLP-1 receptor — the mechanism behind the well-known weight-management and glycemic-control drugs. Cagrilintide works through the amylin/calcitonin receptor system, a satiety pathway that is separate from and complementary to GLP-1. The rationale for combining them is that engaging two independent satiety systems may produce a greater effect than either alone.
Human Evidence
The combination has genuine clinical data behind it, which distinguishes it from many research blends. A Phase 2 study of concomitant cagrilintide and semaglutide was published in The Lancet in 2021. The combination then advanced to Novo Nordisk's Phase 3 REDEFINE program in obesity, with topline results reported in which CagriSema produced greater average weight reduction than either cagrilintide or semaglutide monotherapy and placebo.
Important caveat on the research-grade version: published trial data describes a specific manufactured, dose-controlled formulation studied under clinical conditions. It does not validate the safety, purity, dosing, or bioavailability of a research-chemical blend sold in a vial. Trial results should not be read as evidence about any particular vendor's product.
Regulatory and Enforcement Context
Because CagriSema as a combination is still investigational, it has no approval as a finished product. And while semaglutide itself is approved, its manufacturer has actively pursued sellers of compounded and bulk semaglutide — including litigation against multiple distributors — as approved-drug supply normalized. Researchers should treat semaglutide-containing research products as a category under active brand and regulatory scrutiny, and prioritize vendors with third-party testing and batch-specific Certificates of Analysis.
Sourcing for Research
As a two-peptide co-formulation, CagriSema requires independent verification of both components' identity and purity. We only surface vendors that provide third-party HPLC testing and batch-specific Certificates of Analysis. This combination is currently carried by two vendors in our index.
View the CagriSema product page →Frequently Asked Questions
Is CagriSema FDA-approved?
No. As a combination it is investigational and not approved for any use. Semaglutide alone is approved as specific finished drugs, but neither cagrilintide nor the combination is approved, and research-grade material is not the approved medicine.
How is CagriSema different from semaglutide alone?
It adds cagrilintide, an amylin analog, to semaglutide's GLP-1 action — engaging a second, independent satiety pathway. In the REDEFINE program the combination produced greater weight reduction than either component alone.
Does clinical trial data apply to research-chemical CagriSema?
No. Trial data describes a specific manufactured formulation under clinical conditions. It says nothing about the purity, dosing, or safety of a research-chemical blend, which is sold for laboratory use only.
References
1. Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial." The Lancet, 2021. thelancet.com
2. Novo Nordisk. REDEFINE Phase 3 program in obesity (cagrilintide 2.4 mg + semaglutide 2.4 mg), topline results. novonordisk.com
3. Lau DCW, et al. "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial." The Lancet, 2021. thelancet.com
4. FDA. Medications containing semaglutide — approved drug products and compounding risk alerts. fda.gov
This article contains affiliate links. Aura Protocols may earn a commission if you purchase through these links at no additional cost to you. The combination described is an unapproved, investigational research chemical sold for laboratory research use only — not for human or veterinary use.